Mammoth Biosciences
Mammoth Biosciences to Receive $100M Upfront in Therapeutic CRISPR Gene Editing Deal With Regeneron
Mammoth is also eligible to receive up to $370 million per target in development, as well as regulatory and commercial milestone payments and royalties from product sales.
People in the News at Roche, Mammoth Biosciences, NeoGenomics, Molecular Assemblies, More
Executive appointments, promotions, and departures in omics and molecular diagnostics for the week of Dec. 5, 2022.
Mammoth Biosciences Develops SNP-Detecting CRISPR System for SARS-CoV-2 Variant Surveillance
Premium
The new enzyme was discovered using a metagenomic discovery approach and adapted into a SARS-CoV-2 variant detection assay.
IDbyDNA Nabs Additional Funding for Gene Editing Dx, Biosurveillance Tech
In collaboration with other firms, IDbyDNA is using precision metagenomics to develop a next-generation device for diagnostic testing of emerging infectious diseases.
Aug 27, 2020
Feb 21, 2020